Infiltrating ductal adenocarcinoma of the pancreas, referred to here as “pancreatic cancer,” is
one of the deadliest of all of the solid malignancies. The five-year survival rate in the United …

Background Pancreatoduodenectomy (PD) has a considerable surgical risk for
complications and late metabolic morbidity. Parenchyma-sparing resection of benign tumors …

Intraductal oncocytic papillary neoplasms (IOPNs) are distinct from intraductal papillary
mucinous neoplasms based on characteristic morphologic and genetic features represented …

Objective: This international multicenter cohort study aims to identify recurrence patterns and
treatment of first and second recurrence in a large cohort of patients after pancreatic …

Abstract The existing Intraductal Papillary Mucinous Neoplasm (IPMN) risk stratification
relies on clinical and histological factors, resulting in inaccuracies and leading to suboptimal …

Context.—Macroscopic precursor lesions of the pancreas represent a complex clinical
management problem. Molecular characterization of pancreatic cysts has helped to confirm …

Targeting the RAS pathway remains the holy grail of precision oncology. In the case of
pancreatic ductal adenocarcinomas (PDAC), 90–92% harbor mutations in the oncogene …

The incidence of pancreas cancer is estimated to be 66,440 cases in 2024, making it the
10th most common cancer in the United States. 1 Despite its rare nature, mortality rates …

Simple Summary Pancreatic cysts are being identified with increasing frequency, and the
prevalence increases with age to 10–25% by the 7th decade of life. They also have the …

Pancreatic cystic neoplasms are frequently detected in the general population. Among
these, mucinous cysts, specifically intraductal papillary mucinous neoplasms (IPMN) and …